126 related articles for article (PubMed ID: 21740083)
1. Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.
Wu S; Keresztes RS
Cancer Invest; 2011 Aug; 29(7):460-71. PubMed ID: 21740083
[TBL] [Abstract][Full Text] [Related]
2. Intricacies of bevacizumab-induced toxicities and their management.
Gressett SM; Shah SR
Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
[TBL] [Abstract][Full Text] [Related]
3. Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Herbst RS
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S23-30. PubMed ID: 17239287
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib: gastrointestinal perforation. Known reactions to VEGF inhibitors.
Prescrire Int; 2009 Apr; 18(100):69. PubMed ID: 19585726
[No Abstract] [Full Text] [Related]
5. Antiangiogenic therapy in nonsmall cell lung cancer.
Gutierrez M; Giaccone G
Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
[TBL] [Abstract][Full Text] [Related]
6. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
Socinski MA
Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723
[TBL] [Abstract][Full Text] [Related]
7. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Kurzrock R; Stewart DJ
Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
[TBL] [Abstract][Full Text] [Related]
9. Managing patients treated with bevacizumab combination therapy.
Gordon MS; Cunningham D
Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
[TBL] [Abstract][Full Text] [Related]
10. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
11. Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer.
Gadgeel SM
Clin Lung Cancer; 2012 Mar; 13(2):96-106. PubMed ID: 22056889
[TBL] [Abstract][Full Text] [Related]
12. [Bevacizumab and arterial hypertension or proteinuria: management].
Senellart H; Bennouna J
Rev Mal Respir; 2008 Jun; 25(6):767-72. PubMed ID: 18772832
[TBL] [Abstract][Full Text] [Related]
13. [Surgical management of bevacizumab-associated peritonitis due to perforation].
Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
[TBL] [Abstract][Full Text] [Related]
14. Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer.
Bertino EM; Otterson GA
Lung Cancer; 2010 Dec; 70(3):233-46. PubMed ID: 20888062
[TBL] [Abstract][Full Text] [Related]
15. Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer.
Wozniak A
Crit Rev Oncol Hematol; 2012 May; 82(2):200-12. PubMed ID: 21715183
[TBL] [Abstract][Full Text] [Related]
16. Safety of bevacizumab in patients with metastatic breast cancer.
Hamilton EP; Blackwell KL
Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
[TBL] [Abstract][Full Text] [Related]
17. Novel angiogenesis inhibitors in nonsmall cell lung cancer.
Reinmuth N; Heigener D; Reck M
Curr Opin Oncol; 2015 Mar; 27(2):79-86. PubMed ID: 25602682
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
Sandler AB; Johnson DH; Herbst RS
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
[TBL] [Abstract][Full Text] [Related]
19. [Generation mechanisms and management strategies of adverse reactions to Bevacizumab during cancer treatment].
Ge FJ; Xu JM
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):481-6. PubMed ID: 21029688
[No Abstract] [Full Text] [Related]
20. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]